文献速递头颈部肿瘤放疗放疗物理与技术

头颈癌临床试验注册分析:放疗相关研究机会

Head and Neck Cancer Clinical Research on ClinicalTrials.gov: An Opportunity for Radiation Oncologists.
PubMed 文献 · Adv Radiat Oncol · 2020-11-17

该研究检索ClinicalTrials.gov上全部开放干预性头颈癌(HNC)试验,共841项,分析其研究类型、PI专业、资金来源及是否检验放疗特异性假设。结果显示III期及随机II期试验中仅11.1%检验放疗假设,而系统性治疗假设占77.1%(P < .001);放疗科医生任PI的试验更可能检验放疗假设(20.9% vs 6.0%;P < .001),放疗聚焦试验的联邦与产业资助率均低。

要点

  • III期及随机II期HNC试验中仅11.1%检验放疗特异性假设,系统性治疗假设占77.1%。
  • 放疗科医生任PI的试验检验放疗假设比例更高(20.9% vs 6.0%,P < .001)。
  • 放疗聚焦试验联邦资助10.4%、产业资助2.6%,资助率低。

核心结论

  • III期和随机II期头颈癌试验中放疗特异性假设占少数,多集中于系统性治疗整合,放疗科医生主导与非产业资助可能促进放疗假设纳入试验设计。

研究设计与样本

  • 对ClinicalTrials.gov上全部开放干预性头颈癌试验进行网络检索,检索词为「head and neck cancer」及各HNC亚部位。
  • 采集试验所用 modality、主要研究者(PI)专业、资金来源及是否检验放疗-modality特异性假设。
  • 采用卡方检验和逻辑回归比较组间差异。

主要发现

  • 共841项开放HNC试验,其中根治性人群占47.6%,复发/转移人群占41.9%。
  • 71.7%的试验为I期或非随机II期,III期或随机II期占28.3%。
  • 单臂研究中79.6%纳入系统性治疗,25.2%纳入放疗。
  • III期及随机II期试验中检验放疗特异性假设者占11.1%,系统性治疗相关假设占77.1%(P < .001)。
  • PI为放疗科医生时检验放疗假设的比例为20.9%,否则为6.0%(P < .001)。

关键数值与推荐

  • 放疗聚焦试验中联邦资助占10.4%,产业资助占2.6%。
  • 早期放疗试验多检验新型modality(如立体定向体部放疗、质子治疗),后期试验多检验剂量与分割。

临床怎么用

  • 放疗科医生应更主动担任头颈癌临床试验PI,以提升放疗特异性假设在II–III期试验中的比例。
  • 需拓展非产业资助渠道,支持放疗剂量、分割、正常组织保护和技术的随机研究。

局限性

  • 仅基于ClinicalTrials.gov注册信息,未报告试验结果或发表情况。
  • 未说明检索时间范围及亚部位检索词的具体构成。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Many improvements in head and neck cancer (HNC) outcomes are related to optimization of radiation therapy (RT) dose, fractionation, normal-tissue sparing, and technology. However, prior work has shown that the literature of randomized controlled trials is dominated by industry-sponsored trials that have lower rates of incorporating RT. We characterized HNC clinical trials, hypothesizing that RT-specific research questions may be relatively underrepresented among HNC randomized controlled trials. METHODS AND MATERIALS: A web query of all open interventional trials on www.ClinicalTrials.gov was performed using search terms "head and neck cancer" and specific HNC subsites. Trial details were captured including the modality used, principal investigator (PI) specialty, funding, and whether the study tested a RT-modality specific hypothesis. Chi-square testing and logistic regression were used to compare groups. RESULTS: There were 841 open HNC trials, including definitive (47.6%) and recurrent/metastatic (41.9%) populations. Most trials (71.7%) were phase I or nonrandomized phase II studies, rather than phase III or randomized phase II (28.3%). Among single-arm studies, most (79.6%) incorporated systemic therapy (ST), and fewer (25.2%) incorporated RT. Even fewer phase III and randomized phase II trials tested an RT-specific hypothesis (11.1%), compared with ST-related hypotheses (77.1%; P < .001); trials were more likely to test an RT-hypothesis if the study PI was a radiation oncologist (20.9% vs 6.0%; P < .001). Among RT trials, most early-phase studies tested novel modalities (eg, stereotactic body radiation therapy, proton therapy), whereas most later-phase studies tested dose and fractionation. RT-focused trials had low rates of federal (10.4%) or industry (2.6%) funding. CONCLUSIONS: RT-specific research hypotheses are a minority of phase II-III HNC trials, which mostly focus on incorporating ST in the definitive or recurrent/metastatic setting and have higher rates of industry funding. Radiation oncologist PI leadership and increased nonindustry funding access may ensure that RT-specific hypotheses are incorporated into trial design.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Muralidhar V, Giacalone NJ, Milani N, et al. Head and Neck Cancer Clinical Research on ClinicalTrials.gov: An Opportunity for Radiation Oncologists. Adv Radiat Oncol. 2020. PMID: 33748541. doi:10.1016/j.adro.2020.10.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。